Abstract | OBJECTIVE: DESIGN: Randomized, double-blind comparator trial. SETTING: OUTCOME MEASURES: Demographic data, preblock numerical rating scales (NRSs), the Leeds assessment of neuropathic symptoms and signs (LANSS(0) ) score, accompanying symptoms, and analgesic requirements were recorded. Postblock NRS scores were noted following peripheral nerve block and after 3 months. LANSS(1) , accompanying symptoms, and analgesic requirements were also reevaluated 3 months after the injection. RESULTS: Demographic data, preblock NRS (8 ± 1.5 and 8.1 ± 1.2, respectively), postblock NRS (2.1 ± 1.2 and 2.4 ± 1.4, respectively), LANSS(0) (18.4 ± 2.2 and 18.2 ± 2.1, respectively), and accompanying symptoms were comparable between groups. Scores for the methylprednisolone group were significantly improved at 3-month postblock for NRS (2 ± 1.4 vs 5.2 ± 1.7) and LANSS(1) scores (4.14 ± 2.7 vs 14.1 ± 2.8), accompanying symptoms, and analgesic requirements (P < 0.0001). CONCLUSIONS:
|
Authors | H Evren Eker, Oya Yalcin Cok, Anis Aribogan, Gulnaz Arslan |
Journal | Pain medicine (Malden, Mass.)
(Pain Med)
Vol. 13
Issue 3
Pg. 443-51
(Mar 2012)
ISSN: 1526-4637 [Electronic] England |
PMID | 22313580
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Wiley Periodicals, Inc. |
Chemical References |
- Anesthetics, Local
- Neuroprotective Agents
- Lidocaine
- Methylprednisolone
|
Topics |
- Anesthetics, Local
(administration & dosage)
- Double-Blind Method
- Female
- Humans
- Lidocaine
(administration & dosage)
- Male
- Methylprednisolone
(administration & dosage)
- Middle Aged
- Nerve Block
(methods)
- Neuralgia
(drug therapy, etiology)
- Neuroprotective Agents
(administration & dosage)
- Peripheral Nerve Injuries
(complications, drug therapy)
- Treatment Outcome
|